mavoric: mogamulizumab improves pfs for ctcl
Published 2 years ago • 93 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
0:40
mavoric: long-term clinical benefit of mogamulizumab in patients with ctcl
-
2:31
mavoric trial: mogamulizumab for r/r ctc
-
1:57
key trials in ctcl
-
0:38
link between blood involvement and hrqol in ctcl patients receiving mogamulizumab
-
1:16
treatment of advanced ctcl in 2021
-
32:05
r-chop chemotherapy & dealing with side effects | luis’ story (2 of 3) | the patient story
-
2:36
a day at quinton's labs
-
7:49
mycosis fungoides (cutaneous t-cell lymphoma): 5-minute pathology pearls
-
0:54
maintenance therapy in ctcl
-
7:09
targeted antibody mogamulizumab superior to vorinostat for previously treated ctcl
-
0:43
the future of ctcl therapy
-
1:46
methods to access the clinical efficacy of mogamulizumab
-
13:13
expert perspectives: the mavoric trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:55
post-transplant pd1 blockade plus autologous lymphocytes in r/r hl
-
0:47
overview of the phase iii enhance trial schema
-
3:33
a novel composite endpoint of toxicity and pfs in patients with r/r fl treated with axi-cel
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
2:04
autologous transplantation followed by maintenance vs maintenance alone in patients with mcl
-
1:14
highlights in quality management from ebmt
-
0:45
difference between quality of life & patient-reported outcomes